Top

Published in:

01-11-2003 | Clinical commentary

Is there a role for dehydroepiandrosterone replacement in the intensive care population?

Author: Ketan K. Dhatariya

Published in: Intensive Care Medicine | Issue 11/2003

Excerpt

Adrenal insufficiency in the intensive care population is becoming recognised as a cause of the increased morbidity and mortality seen in these patients. However, currently there is no consensus as to what constitutes 'adrenal insufficiency' in critically ill patients. Most authors agree that the condition is diagnosed by the lack of an appropriate rise in circulating cortisol after adrenal stimulation with an intravenous bolus of synthetic adrenocorticotrophic hormone (ACTH). However, there remain controversies over what dose of synthetic ACTH to use (1 or 250 µg), and what should be the cut-off point in cortisol levels that definitively diagnoses someone as being hypoadrenal. …

Barquist E, Kirton O (1997) Adrenal insufficiency in the surgical intensive care unit patient. J Trauma 42:27–31PubMed

Annane D, Sebille V, Charpentier C, Bollaert PE, Francois B, Korach JM, Capellier G, Cohen Y, Azoulay E, Chaumet-Riffaut P, Bellissant E (2002) Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA 288:862–871PubMed

Zipser RD, Davenport MW, Martin KL, Tuck ML, Warner NE, Swinney RR, Davis CL, Horton R (1981) Hyperreninemic hypoaldosteronism in the critically ill: a new entity. J Clin Endocrinol Metab 53:867–873

Findling JW, Waters VO, Raff H (1987) The dissociation of renin and aldosterone during critical illness. J Clin Endocrinol Metab 64:592–595

Kilger E, Weis F, Briegel J, Frey L, Goetz AE, Nagy A, Schuetz A, Lamm P, Knoll A, Peter K (2003) Stress doses of hydrocortisone reduce severe systemic inflammatory response syndrome and improve early outcome in a risk group of patients after cardiac surgery. Crit Care Med 31:1068–1074PubMed

Briegel J, Forst H, Haller M, Schelling G, Kilger E, Kuprat G, Hemmer B, Hummel T, Lenhart A, Heyduck M, Stoll C, Peter K (1999) Stress doses of hydrocortisone reverse hyperdynamic septic shock: a prospective, randomized, double-blind, single-center study. Crit Care Med 27:723–732PubMed

Labrie F (1991) Intracrinology. Mol Cell Endocrinol 78:C113–118CrossRefPubMed

Orentreich N, Brind JL, Rizer RL, Vogelman JH (1984) Age changes and sex differences in serum dehydroepiandrosterone sulfate concentrations throughout adulthood. J Clin Endocrinol Metab 59:551–555PubMed

Hornsby PJ (2002) Aging of the human adrenal cortex. Ageing Res Rev 1:229–242CrossRefPubMed

10.

Dhatariya K, Nair KS (2003) DHEA—Is there a role for replacement? Mayo Clin Proc (in press):

11.

Vermes I, Beishuizen A, Hampsink RM, Haanen C (1995) Dissociation of plasma adrenocorticotropin and cortisol levels in critically ill patients: possible role of endothelin and atrial natriuretic hormone. J Clin Endocrinol Metab 80:1238–1242PubMed

12.

Schroeder S, Wichers M, Klingmuller D, Hofer M, Lehmann LE, von Spiegel T, Hering R, Putensen C, Hoeft A, Stuber F (2001) The hypothalamic-pituitary-adrenal axis of patients with severe sepsis: altered response to corticotropin-releasing hormone. Crit Care Med 29:310–316PubMed

13.

Annane D (2001) Corticosteroids for septic shock. Crit Care Med 29:S117–120PubMed

14.

Marx C, Petros S, Bornstein SR, Weise M, Wendt M, Menschikowski M, Engelmann E, Höffken G (2003) Adrenocortical hormones in survivors and nonsurvivors of severe sepsis: diverse time course of dehydroepiandrosterone, dehydroepiandrosterone-sulfate, and cortisol. Crit Care Med 31:1382–1388PubMed

15.

Beishuizen A, Thijs LG, Vermes I (2002) Decreased levels of dehydroepiandrosterone sulphate in severe critical illness: a sign of exhausted adrenal reserve? Crit Care 6:434–438CrossRefPubMed

16.

Delpedro AD, Barjavel MJ, Mamdouh Z, Bakouche O (1998) Activation of human monocytes by LPS and DHEA. J Interferon Cytokine Res 18:125–135PubMed

17.

Blauer KL, Poth M, Rogers WM, Bernton EW (1991) Dehydroepiandrosterone antagonizes the suppressive effects of dexamethasone on lymphocyte proliferation. Endocrinology 129:3174–3179PubMed

18.

Meikle AW, Dorchuck RW, Araneo BA, Stringham JD, Evans TG, Spruance SL, Daynes RA (1992) The presence of a dehydroepiandrosterone-specific receptor binding complex in murine T cells. J Steroid Biochem Mol Biol 42:293–304PubMed

19.

Oberbeck R, Dahlweid M, Koch R, van Griensven M, Emmendorfer A, Pape HC (2001) Dehydroepiandrosterone decreases mortality rate and improves cellular immune function during polymicrobial sepsis. Crit Care Med 29:380–384PubMed

20.

Suzuki T, Suzuki N, Daynes RA, Engleman EG (1991) Dehydroepiandrosterone enhances IL2 production and cytotoxic effector function of human T cells. Clin Immunol Immunopathol 61:202–211PubMed

21.

Casson PR, Andersen RN, Herrod HG, Stentz FB, Straughn AB, Abraham GE, Buster JE (1993) Oral dehydroepiandrosterone in physiologic doses modulates immune function in postmenopausal women. Am J Obstet Gynecol 169:1536–1539PubMed

22.

Morales AJ, Nolan JJ, Nelson JC, Yen SS (1994) Effects of replacement dose of dehydroepiandrosterone in men and women of advancing age. J Clin Endocrinol Metab 78:1360–1367PubMed

23.

Montori VM, Bistrian BR, McMahon MM (2002) Hyperglycemia in Acutely Ill Patients. JAMA 288:2167–2169CrossRefPubMed

24.

Van den Berghe G, Wouters P, Weekers F, Verwaest C, Bruyninckx F, Schetz M, Vlasselaers D, Ferdinande P, Bouillon R, Lauwers P (2001) Intensive insulin therapy in the surgical intensive care unit. N Engl J Med 345:1359–1367PubMed

25.

Van den Berghe G, Wouters P, Weekers F, Mohan S, Baxter RC, Veldhuis JD, Bowers CY, Bouillon R (1999) Reactivation of Pituitary Hormone Release and Metabolic Improvement by Infusion of Growth Hormone-Releasing Peptide and Thyrotropin-Releasing Hormone in Patients with Protracted Critical Illness. J Clin Endocrinol Metab 84:1311–1323

26.

Shepherd A, Cleary MP (1984) Metabolic alterations after dehydroepiandrosterone treatment in Zucker rats. Am J Physiol Endocrinol Metab 246:E123–128

27.

Kajita K, Ishizuka T, Miura A, Ishizawa M, Kanoh Y, Yasuda K (2000) The role of atypical and conventional PKC in dehydroepiandrosterone-induced glucose uptake and dexamethasone-induced insulin resistance. Biochem Biophys Res Commun 277:361–367CrossRefPubMed

28.

Herranz L, Megia A, Grande C, Gonzalez-Gancedo P, Pallardo F (1995) Dehydroepiandrosterone sulphate, body fat distribution and insulin in obese men. Int J Obes Relat Metab Disord 19:57–60PubMed

Title: Is there a role for dehydroepiandrosterone replacement in the intensive care population?
Author: Ketan K. Dhatariya
Publication date: 01-11-2003
Publisher: Springer-Verlag
Published in: Intensive Care Medicine / Issue 11/2003
Print ISSN: 0342-4642
Electronic ISSN: 1432-1238
DOI: https://doi.org/10.1007/s00134-003-1981-y

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Is there a role for dehydroepiandrosterone replacement in the intensive care population?

Excerpt

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 11/2003

Measurement of diaphragm loading during pressure support ventilation

Acute community-acquired bacterial meningitis in adults admitted to the intensive care unit: clinical manifestations, management and prognostic factors

Early antibiotic treatment (prophylaxis) of septic complications in severe acute necrotizing pancreatitis: a prospective, randomized, multicenter study comparing two regimens with imipenem-cilastatin

Triggering and cycling off during pressure support ventilation: simplicity or sophistication?

Accidental methadone overdose in an opiate-naive elderly patient

A 7-year study of severe hospital-acquired pneumonia requiring ICU admission